Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo

You-Sin Jian, Ching-Wen Chen, Chih-An Lin, Hsiu-Ping Yu, Hua-Yang Lin, Ming-Yuan Liao, Shu-Huan Wu, Yan-Fu Lin, Ping-Shan Lai, You-Sin Jian, Ching-Wen Chen, Chih-An Lin, Hsiu-Ping Yu, Hua-Yang Lin, Ming-Yuan Liao, Shu-Huan Wu, Yan-Fu Lin, Ping-Shan Lai

Abstract

Carrier-mediated drug delivery systems are promising therapeutics for targeted delivery and improved efficacy and safety of potent cytotoxic drugs. Nimesulide is a multifactorial cyclooxygenase 2 nonsteroidal anti-inflammatory drug with analgesic, antipyretic and potent anticancer properties; however, the low solubility of nimesulide limits its applications. Drugs conjugated with hyaluronic acid (HA) are innovative carrier-mediated drug delivery systems characterized by CD44-mediated endocytosis of HA and intracellular drug release. In this study, hydrophobic nimesulide was conjugated to HA of two different molecular weights (360 kDa as HA with high molecular weight [HAH] and 43kDa as HA with low molecular weight [HAL]) to improve its tumor-targeting ability and hydrophilicity. Our results showed that hydrogenated nimesulide (N-[4-amino-2-phenoxyphenyl]methanesulfonamide) was successfully conjugated with both HA types by carbodiimide coupling and the degree of substitution of nimesulide was 1%, which was characterized by 1H nuclear magnetic resonance 400 MHz and total correlation spectroscopy. Both Alexa Fluor® 647 labeled HAH and HAL could selectively accumulate in CD44-overexpressing HT-29 colorectal tumor area in vivo, as observed by in vivo imaging system. In the in vitro cytotoxic test, HA-nimesulide conjugate displayed >46% cell killing ability at a nimesulide concentration of 400 µM in HT-29 cells, whereas exiguous cytotoxic effects were observed on HCT-15 cells, indicating that HA-nimesulide causes cell death in CD44-overexpressing HT-29 cells. Regarding in vivo antitumor study, both HAL-nimesulide and HAH-nimesulide caused rapid tumor shrinkage within 3 days and successfully inhibited tumor growth, which reached 82.3% and 76.4% at day 24 through apoptotic mechanism in HT-29 xenografted mice, without noticeable morphologic differences in the liver or kidney, respectively. These results indicated that HA-nimesulide with improved selectivity through HA/CD44 receptor interactions has the potential to enhance the therapeutic efficacy and safety of nimesulide for cancer treatment.

Keywords: CD44; COX-2 inhibitor; colorectal cancer; hyaluronic acid; nimesulide.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Schematic illustration of the synthesis of (A) NiNH2 and (B) HA–nimesulide conjugates. Abbreviations: EA, ethyl acetate; EDC, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide; HA, hyaluronic acid; h, hours; NHS, N-hydroxysuccinimide; NiNH2, N-(4-amino-2-phenoxyphenyl)methanesulfonamide.
Figure 2
Figure 2
1H NMR spectra of NiNO2 (nimesulide) and NiNH2. Abbreviations: NiNH2, N-(4-amino-2-phenoxyphenyl)methanesulfonamide; NMR, nuclear magnetic resonance.
Figure 3
Figure 3
1H NMR spectra of (A) NiNH2, (B) HAL–nimesulide-1%, (C) HAH–nimesulide-1% and (D) free HAH. Abbreviations: NiNH2, N-(4-amino-2-phenoxyphenyl)methanesulfonamide; NMR, nuclear magnetic resonance; HA, hyaluronic acid; HAH, HA with high molecular weight; HAL, HA with low molecular weight.
Figure 4
Figure 4
TOCSY (bold line) results for HA–nimesulide conjugate. Abbreviations: HA, hyaluronic acid; TOCSY, total correlation spectroscopy.
Figure 5
Figure 5
(A) Flow cytometry analysis of CD44 expression in HT-29 and HCT-15 cells; (B) immunocytochemistry of CD44 expression in HT-29 or HCT-15 cells assessed by confocal microscopy at a concentration of 1 µM CD44-FITC or 1 mg/mL HA-dye. Intracellular distribution of HAH-ADH-FITC at 3, 6 and 24 h posttreatment in (C) HT-29 and (D) HCT-15 cells. Hoechst 33342 (shown in blue) is used for nuclei labeling. CD44-FITC or HAH-ADH-FITC is shown in green. Scale bar: 10 µm. Abbreviations: ADH, adipic acid dihydrazide; FITC, fluorescein isothiocyanate; HA, hyaluronic acid; HAH, HA with high molecular weight.
Figure 6
Figure 6
In vivo fluorescence imaging of HA-NIR dye with different molecular weight of HA. Notes: (A) Time-dependent distribution of HA-NIR was measured by the IVIS Xenogen imaging system after HA-NIR dye administration intravenously (HA-NIR dye: 20 mg/mL, 200 mg/kg). (B) Quantification of fluorescence signal on the tumor site (n=3). (C) Fluorescence spectra of HAH-NIR, HAL-NIR and dye. (D) The fluorescence images of each organ and (E) fluorescence quantification of the tumor images of mice treated with HAL-NIR, HAH-NIR or free dye at 48 h postinjection (n=3). Abbreviations: HA, hyaluronic acid; HAH, HA with high molecular weight; HAL, HA with low molecular weight; IVIS, in vivo imaging system; min, minimum, max, maximum; ROI, region of interest.
Figure 6
Figure 6
In vivo fluorescence imaging of HA-NIR dye with different molecular weight of HA. Notes: (A) Time-dependent distribution of HA-NIR was measured by the IVIS Xenogen imaging system after HA-NIR dye administration intravenously (HA-NIR dye: 20 mg/mL, 200 mg/kg). (B) Quantification of fluorescence signal on the tumor site (n=3). (C) Fluorescence spectra of HAH-NIR, HAL-NIR and dye. (D) The fluorescence images of each organ and (E) fluorescence quantification of the tumor images of mice treated with HAL-NIR, HAH-NIR or free dye at 48 h postinjection (n=3). Abbreviations: HA, hyaluronic acid; HAH, HA with high molecular weight; HAL, HA with low molecular weight; IVIS, in vivo imaging system; min, minimum, max, maximum; ROI, region of interest.
Figure 7
Figure 7
(A) Cell viability assessment of NiNH2 and NiNO2 (nimesulide) in HT-29 and HCT-15 cells. (B) Viability of HT-29 cells in HAL–nimesulide-1% or HAH–nimesulide-1% for 48 h and (C) cell viability of HT-29 and HCT-15 cells treated with HAH–nimesulide-1% for 48 h. Abbreviations: NiNH2, N-(4-amino-2-phenoxyphenyl)methanesulfonamide; HA, hyaluronic acid; HAH, HA with high molecular weight; HAL, HA with low molecular weight.
Figure 8
Figure 8
Apoptotic analysis of HT-29 cells using Annexin V-FITC and PI double staining. Notes: (A) Negative control group; (B) cells treated with H2O2 at 10 mM as positive control group and (C) cells treated with HAL–nimesulide at 200 µM nimesulide concentration for 48 h. The X-axis represents the density of Annexin V-FITC, whereas the Y-axis represents the density of PI. Abbreviations: FITC, fluorescein isothiocyanate; PI, propidium iodide; HA, hyaluronic acid; HAL, HA with low molecular weight.
Figure 9
Figure 9
In vivo antitumor effects of HA–nimesulide in nude mice bearing HT-29 xenografts. Notes: Nude mice were implanted subcutaneously with HT-29 cells and treated three times weekly with 0.2 mL PBS, nimesulide (1.5 mg/kg), HA–nimesulide (1.5 mg/kg equivalent nimesulide concentration) or 5-FU (50 mg/kg) once per week. (A) Tumor size and (B) body weight of mice after treatment with drugs. (C) Organ morphology, tumor weight and (D) TGI % after treatment with drugs. Statistical significances were determined using the One-way ANOVA followed by Bonferroni tests, *P<0.05. Abbreviations: 5-FU, 5-fluorouracil; ANOVA, analysis of variance; HA, hyaluronic acid; HAH, HA with high molecular weight; HAL, HA with low molecular weight; PBS, phosphate-buffered saline; TGI, tumor growth inhibition.
Figure 10
Figure 10
Histologic assessment of liver, kidney and tumor after treatment with PBS, 5-FU, nimesulide or HA–nimesulide in nude mice bearing HT-29 xenografts (400×). Abbreviations: 5-FU, 5-fluorouracil; HA, hyaluronic acid; PBS, phosphate-buffered saline.
Figure 11
Figure 11
Detection of DNA strand breaks by TUNEL assay in nude mice bearing HT-29 xenografts treated with PBS, nimesulide or HAH–nimesulide. Abbreviations: HA, hyaluronic acid; HAH, HA with high molecular weight; PBS, phosphate-buffered saline; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end-labeling.

References

    1. Chang YT, Tseng HC, Huang CC, et al. Relative down-regulation of apoptosis and autophagy genes in colorectal cancer. Eur J Clin Invest. 2011;41(1):84–92.
    1. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351.
    1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–1047.
    1. Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer. 2010;46(10):1900–1909.
    1. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta. 2006;1766(2):184–196.
    1. Herrera-Gayol A, Jothy S. Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol. 1999;66(2):149–156.
    1. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol. 1999;52(4):189–196.
    1. Alves CS, Yakovlev S, Medved L, Konstantopoulos K. Biomolecular characterization of CD44-fibrin(ogen) binding: distinct molecular requirements mediate binding of standard and variant isoforms of CD44 to immobilized fibrin(ogen) J Biol Chem. 2009;284(2):1177–1189.
    1. Cheng C, Sharp PA. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol. 2006;26(1):362–370.
    1. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell-surface receptor for hyaluronate. Cell. 1990;61(7):1303–1313.
    1. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33–45.
    1. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104(24):10158–10163.
    1. Merlos-Suarez A, Barriga FM, Jung P, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell. 2011;8(5):511–524.
    1. Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 2012;28(4):1301–1308.
    1. Misra S, Heldin P, Hascall VC, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011;278(9):1429–1443.
    1. Liu K, Wang ZQ, Wang SJ, et al. Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation. Int J Nanomedicine. 2015;10:6445–6454.
    1. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem. 2002;277(7):4589–4592.
    1. Segura T, Anderson BC, Chung PH, Webber RE, Shull KR, Shea LD. Crosslinked hyaluronic acid hydrogels: a strategy to functionalize and pattern. Biomaterials. 2005;26(4):359–371.
    1. Underhill C. CD44: the hyaluronan receptor. J Cell Sci. 1992;103(Pt 2):293–298.
    1. Kawada C, Yoshida T, Yoshida H, et al. Ingested hyaluronan moisturizes dry skin. Nutr J. 2014;13:70.
    1. Kota DJ, Prabhakara KS, Cox CS, Olson SD. MSCs and hyaluronan: sticking together for new therapeutic potential? Int J Biochem Cell Biol. 2014;55:1–10.
    1. Allison DD, Grande-Allen KJ. Review. Hyaluronan: a powerful tissue engineering tool. Tissue Eng. 2006;12(8):2131–2140.
    1. Song S, Qi H, Xu J, et al. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm Res. 2014;31(11):2988–3005.
    1. Xu K, Lee F, Gao SJ, Chung JE, Yano H, Kurisawa M. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-alpha2a for liver cancer therapy. J Control Release. 2013;166(3):203–210.
    1. Yoon HY, Kim HR, Saravanakumar G, et al. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting. J Control Release. 2013;172(3):653–661.
    1. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci. 2011;359(1):318–325.
    1. Saravanakumar G, Deepagan VG, Jayakumar R, Park JH. Hyaluronic acid-based conjugates for tumor-targeted drug delivery and imaging. J Biomed Nanotechnol. 2014;10(1):17–31.
    1. Lee H, Lee K, Park TG. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem. 2008;19(6):1319–1325.
    1. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006;85(8):699–715.
    1. Cowman MK, Matsuoka S. Experimental approaches to hyaluronan structure. Carbohydr Res. 2005;340(5):791–809.
    1. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985;228(4705):1324–1326.
    1. Rothman I, Stanford JL, Kuniyuki A, Berger RE. Self-report of prostatitis and its risk factors in a random sample of middle-aged men. Urology. 2004;64(5):876–879. discussion 879–880.
    1. Loftus EV., Jr Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006;35(3):517–531.
    1. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1994;48(3):431–454.
    1. Gianiorio P, Zappa R, Sacco O, Fregonese B, Scaricabarozzi I, Rossi GA. Antipyretic and anti-inflammatory efficacy of nimesulide vs paracetamol in the symptomatic treatment of acute respiratory infections in children. Drugs. 1993;46(Suppl 1):204–207.
    1. Okajima E, Denda A, Ozono S, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res. 1998;58(14):3028–3031.
    1. Fukutake M, Nakatsugi S, Isoi T, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis. 1998;19(11):1939–1942.
    1. Nakatsugi S, Ohta T, Kawamori T, et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Cancer Sci. 2000;91(9):886–892.
    1. Furukawa F, Nishikawa A, Lee IS, et al. A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl) amine-induced pancreatic carcinogenesis in hamsters. Int J Cancer. 2003;104(3):269–273.
    1. Li JY, Wang XZ, Chen FL, Yu JP, Luo HS. Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol. 2003;9(5):915–920.
    1. Jia-Jun T, Su-Mei L, Liang Y, et al. Nimesulide inhibited the growth of hypopharyngeal carcinoma cells via suppressing survivin expression. Head Neck Oncol. 2012;4:7.
    1. Zhong B, Cai X, Chennamaneni S, et al. From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation. Eur J Med Chem. 2012;47(1):432–444.
    1. Li XH, Li JJ, Zhang HW, et al. Nimesulide inhibits tumor growth in mice implanted hepatoma: overexpression of Bax over Bcl-2. Acta Pharmacol Sin. 2003;24(10):1045–1050.
    1. Fallavena PRB, Schapoval EES. pKa determination of nimesulide in methanol-water mixtures by potentiometric titrations. Int J Pharm. 1997;158(1):109–112.
    1. Neha A, Singh I, Sharma M, Tarun G. An approach for improvement of the water solubility of nimesulide in solid dispersion with PEG. IOSR J Pharm. 2012;2(2):153–154.
    1. Macpherson D, Best SA, Gedik L, Hewson AT, Rainsford K, Parisi S. The biotransformation and pharmacokinetics of 14C-nimesulide in humans following a single dose oral administration. J Drug Metab Toxicol. 2013;4:140.
    1. Luo L, Tao W, Bourkaib N, Luo Y. Design and content determination of nimesulide injectable formulation. Pak J Pharm Sci. 2015;28(4):1195–1201.
    1. Cignarella G, Vianello P, Berti F, Rossoni G. Synthesis and pharmacological evaluation of derivatives structurally related to nimesulide. Eur J Med Chem. 1996;31(5):359–364.
    1. Pericherla S, Mareddy J, Rani DPR, Gollapudi PV, Pal S. Chemical modifications of nimesulide. J Brazil Chem Soc. 2007;18(2):384–390.
    1. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules. 2000;1(2):208–218.
    1. Lim EK, Kim HO, Jang E, et al. Hyaluronan-modified magnetic nanoclusters for detection of CD44-overexpressing breast cancer by MR imaging. Biomaterials. 2011;32(31):7941–7950.
    1. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem. 1999;10(5):755–763.
    1. Pouyani T, Prestwich GD. Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. Bioconjug Chem. 1994;5(4):339–347.
    1. National Research Council (U.S). Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S), National Academies Press (U.S.) Guide for the Care and use of Laboratory Animals. Washington, D.C: National Academies Press; 2011.
    1. Nakajima TE, Yasunaga M, Kano Y, et al. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int J Cancer. 2008;122(9):2148–2153.
    1. Sharma R, Adam E, Schumacher U. The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. Br J Cancer. 1997;76(8):1011–1016.
    1. Leonelli F, La Bella A, Francescangeli A, et al. A new and simply available class of hydrosoluble bioconjugates by coupling paclitaxel to hyaluronic acid through a 4-hydroxybutanoic acid derived linker. Helv Chim Acta. 2005;88(1):154–159.
    1. Cai S, Alhowyan AAB, Yang Q, Forrest WCM, Shnayder Y, Forrest ML. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates. J Drug Target. 2014;22(7):648–657.
    1. Wang W, Cameron AG, Ke S. Developing fluorescent hyaluronan analogs for hyaluronan studies. Molecules. 2012;17(2):1520–1534.
    1. Zhao MD, Cheng JL, Yan JJ, et al. Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation. Int J Nanomedicine. 2016;11:1323–1336.
    1. El-Dakdouki MH, Xia J, Zhu DC, et al. Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles. ACS Appl Mater Interfaces. 2014;6(1):697–705.
    1. Shi J, Ma R, Wang L, et al. The application of hyaluronic acid-derivatized carbon nanotubes in hematoporphyrin monomethyl ether-based photodynamic therapy for in vivo and in vitro cancer treatment. Int J Nanomedicine. 2013;8:2361–2373.
    1. Carini M, Aldini G, Stefani R, Marinello C, Facino RM. Mass spectrometric characterization and HPLC determination of the main urinary metabolites of nimesulide in man. J Pharm Biomed Anal. 1998;18(1–2):201–211.
    1. Mizuno K, Katoh M, Okumura H, et al. Metabolic activation of benzodiazepines by CYP3A4. Drug Metab Dispos. 2009;37(2):345–351.
    1. Demiryilmaz I, Turan MI, Kisaoglu A, Gulapoglu M, Yilmaz I, Suleyman H. Protective effect of nimesulide against hepatic ischemia/reperfusion injury in rats: effects on oxidant/antioxidants, DNA mutation and COX-1/COX-2 levels. Pharmacol Rep. 2014;66(4):647–652.
    1. Licata A, Calvaruso V, Cappello M, Craxi A, Almasio PL. Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. Dig Liver Dis. 2010;42(2):143–148.
    1. Mingatto FE, Rodrigues T, Pigoso AA, Uyemura SA, Curti C, Santos AC. The critical role of mitochondrial energetic impairment in the toxicity of nimesulide to hepatocytes. J Pharmacol Exp Ther. 2002;303(2):601–607.
    1. Mingatto FE, dos Santos AC, Rodrigues T, Pigoso AA, Uyemura SA, Curti C. Effects of nimesulide and its reduced metabolite on mitochondria. Br J Pharmacol. 2000;131(6):1154–1160.
    1. Li F, Chordia MD, Huang T, Macdonald TL. In vitro nimesulide studies toward understanding idiosyncratic hepatotoxicity: diiminoquinone formation and conjugation. Chem Res Toxicol. 2009;22(1):72–80.
    1. Shaik MS, Chatterjee A, Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res. 2004;10(4):1521–1529.
    1. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14(21):6751–6760.
    1. Wielenga VJ, Heider KH, Offerhaus GJ, et al. Expression of CD44 variant proteins in human colorectal-cancer is related to tumor progression. Cancer Res. 1993;53(20):4754–4756.
    1. Li W, Yi X, Liu X, Zhang Z, Fu Y, Gong T. Hyaluronic acid ionpairing nanoparticles for targeted tumor therapy. J Control Release. 2016;225:170–182.
    1. Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33(20):2279–2287.
    1. Poveda AM, Selle F, Hilpert F, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol. 2015;33(32):3836–3838.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi